Webinar: ctDNA for minimal residual disease research
In this webinar, we will explain how IDT's hybridization capture solutions are assisting researchers with overcoming challenges associated with circulating tumor DNA (ctDNA) for minimal residual disease (MRD) research.
Online
In this webinar, we will explain how IDT's hybridization capture solutions are assisting researchers with overcoming challenges associated with circulating tumor DNA (ctDNA) for minimal residual disease (MRD) research. You will also gain insights about the importance of minimal residual disease research, how it compares to traditional methods, and the impact it is making with the discovery of new biomarkers. We hope by bringing these studies into the spotlight, it will foster new collaborations and discoveries within oncology research.
In this webinar you will learn:
- What minimal residual disease is
- How MRD analysis compares to traditional methods when analyzing disease recurrence
- How ctDNA is being used as a potential biomarker for monitoring residual disease
Speakers:
Haimeng Tang - Bioinformatician, Geneseeq
Haimeng has a B.S. in Biotechnology from the University of Toronto and obtained his MS from Brock University in 2021. His work focuses on genetic markers for drug resistance, MRD detection, and early detection of cancers.
Jordan Young - Manager, Strategic Marketing , Integrated DNA Technologies
Jordan leads IDT's account-based marketing programs and is responsible for establishing new partnerships and collaborations with institutions and researchers around the world. Prior to IDT, he held multiple positions ranging from product management to sales in cell biology, genomics, and medical devices. Jordan has a BS in Applied Biology and an MBS with a focus in life sciences and biotechnology.
When: Wednesday, April 19, 2023, 17.00 CEST
Where: Online (free)
Want to know more about Minimal residual disease (MRD) research?